CSBTF OTC
Kuros Biosciences AG
1W: +0.0%
1M: -11.1%
3M: +5.6%
YTD: -37.4%
1Y: -15.2%
3Y: +1150.0%
5Y: +879.6%
$24.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$121M
+60.6% ▲
5Y CAGR: +97.5%
Gross Profit
$105M
+69.0% ▲
5Y CAGR: +128.8%
Operating Income
$7M
+246.8% ▲
Net Income
$2M
+157.0% ▲
EPS (Diluted)
$0.05
+151.3% ▲
EBITDA
$10M
+1906.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $14M | $18M | $34M | $76M | $121M |
| YoY Growth | +242.0% | +30.2% | +86.6% | +125.1% | +60.6% |
| Cost of Revenue | $4M | $7M | $5M | $14M | $17M |
| Gross Profit | $10M | $11M | $28M | $62M | $105M |
| Gross Margin | 72.9% | 59.9% | 84.8% | 82.1% | 86.4% |
| R&D Expenses | $5M | $5M | $6M | $7M | $9M |
| SG&A Expenses | $7M | $11M | $21M | $41M | $89M |
| Operating Expenses | $19M | $24M | $42M | $67M | $98M |
| Operating Income | -$9M | -$13M | -$13M | -$5M | $7M |
| Operating Margin | -63.5% | -74.8% | -39.3% | -6.6% | 6.0% |
| Interest Expense | $1M | $4M | -$2M | $149K | $305K |
| Income Before Tax | -$10M | -$16M | -$10M | -$3M | $4M |
| Tax Expense | -$2M | -$1M | $380K | $370K | $2M |
| Net Income | -$8M | -$15M | -$14M | -$4M | $2M |
| Net Margin | -54.6% | -81.1% | -40.9% | -4.9% | 1.7% |
| EPS (Diluted) | $-0.23 | $-0.43 | $-0.38 | $-0.10 | $0.05 |
| EBITDA | -$5M | -$8M | -$7M | -$561K | $10M |
| Shares Outstanding | 33M | 34M | 37M | 37M | 41M |